Overview
Thoracic herpes zoster (shingles) is a reactivation of varicella-zoster virus (VZV) affecting the thoracic dermatomes, leading to painful vesicular rash and potential complications such as post-herpetic neuralgia 3.Diagnosis
Clinical presentation includes unilateral vesicular rash and pain in a dermatomal distribution 3.
Laboratory tests typically not required for diagnosis but may include VZV antibody testing for epidemiological purposes 3.
No specific grading system mentioned for diagnostic criteria 3.Management
First-line treatments:
- Topical idoxuridine for localized lesions 3.
- Intravenous acyclovir for younger patients with complications or immunosuppression 3.
Adjunctive treatments:
- High-dose intravenous acyclovir for severe cases or immunocompromised patients 3.
- Pain management strategies including analgesics and possibly anticonvulsants for neuropathic pain 3.Special Populations
Elderly: Offer topical idoxuridine or intravenous acyclovir to reduce post-herpetic neuralgia risk 3.
Immunocompromised: Require high-dose intravenous acyclovir for effective management 3.
Pregnancy and pediatrics: Not specifically addressed in provided abstracts 12.Key Recommendations
Offer topical idoxuridine or intravenous acyclovir to patients over 50 with uncomplicated shingles to reduce post-herpetic neuralgia risk (Evidence: Strong 3).
For younger patients or those with complications, administer high-dose intravenous acyclovir (Evidence: Strong 3).
Consider concomitant administration of zoster vaccine live with quadrivalent influenza vaccine without significant immunogenicity compromise (Evidence: Moderate 2).References
1 Almofti YA, Ibrahim AA, Mahmoud NA, Elshafei AM, Ibrahim N, Albokhadaim I et al.. Exploring varicella zoster virus proteome for construction and validation of a multi-epitope based subunit vaccine using multifaceted immunoinformatics approaches. PloS one 2025. link
2 Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E et al.. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine 2018. link
3 Peto T. Shingles in general practice. The Practitioner 1989. link